Telix Pharmaceuticals Limited (TLX)
NASDAQ
Healthcare
Biotechnology
$11.29
▲ +2.45%
Market Cap
$3.82B
Sector
Healthcare
Industry
Biotechnology
Beta
0.63
52-Wk Range
6.28-16.94
CEO
Christian Behrenbruch
Country
AU
Currency
USD
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatme…
Open full interactive analysis & DCF →